|
1
|
Zhang M, Yin J and Zhang X: Factors
associated with interstitial lung disease in patients with
rheumatoid arthritis: A systematic review and meta-analysis. PLoS
One. 18(e0286191)2023.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Farquhar HJ, Beckert L, Edwards AL,
Matteson EL, Frampton CMA, Ganly E, Yetton R, Thiessen R, Haslett
J, Bucknall D and Stamp LK: Rheumatoid interstitial lung disease in
Canterbury, Aotearoa New Zealand-A retrospective cohort study.
Semin Arthritis Rheum. 64(152359)2024.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Wang HF, Wang YY, Li ZY, He PJ, Liu S and
Li QS: The prevalence and risk factors of rheumatoid
arthritis-associated interstitial lung disease: A systematic review
and meta-analysis. Ann Med. 56(2332406)2024.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Juge PA, Wemeau L, Ottaviani S, Desjeux G,
Zhuo J, Vannier-Moreau V, Flipo RM, Crestani B and Dieudé P:
Increased mortality in patients with RA-associated interstitial
lung disease: Data from a French administrative healthcare
database. RMD Open. 9(e003491)2023.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Sullivan DI and Ascherman DP: Rheumatoid
arthritis-associated interstitial lung disease (RA-ILD): Update on
prevalence, risk factors, pathogenesis, and therapy. Curr Rheumatol
Rep. 26:431–449. 2024.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Narváez J: Moving forward in Rheumatoid
arthritis-associated interstitial lung disease screening. J Clin
Med. 13(5385)2024.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Koduri G and Solomon JJ: Identification,
monitoring, and management of rheumatoid arthritis-associated
interstitial lung disease. Arthritis Rheumatol. 75:2067–2077.
2023.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Liu M, Jiang Z, Liu M, Ni H, Li Y, Fang J,
Du Q and Dong Y: SLAMF1 as a novel molecule mediating the causal
association between rheumatoid arthritis and interstitial lung
disease: A Mendelian randomization study combined with
transcriptomics and in vivo validation. Int Immunopharmacol. 142
(Pt A)(113082)2024.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Zhong X, Wang X, Xu L, Zhang J, Yu W, Ji
L, Huang J, Zhong X, Zhang J and Long L: Alterations in gut
microbiota in Rheumatoid arthritis patients with interstitial lung
Disease: A Comparative study. Hum Immunol.
86(111239)2025.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Kim Y, Yang HI and Kim KS: Etiology and
pathogenesis of rheumatoid arthritis-interstitial lung disease. Int
J Mol Sci. 24(14509)2023.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Zheng W, Hu X, Zou M, Hu N, Song W, Wang
R, Liu Y, Hou Q, Liu Y, Chen X and Cheng Z: Plasma IL-36α and
IL-36γ as potential biomarkers in interstitial lung disease
associated with rheumatoid arthritis: A pilot study in the Chinese
population. Inflammation. 46:285–296. 2023.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Bes C, Köybaşı G, İçaçan OC, Yalçın Mutlu
M and Yıldırım F: Antifibrotic therapies in rheumatoid arthritis
associated interstitial lung disease. Eur J Rheumatol. 9:176–179.
2022.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Liang B, Zhang Y, Ke D, Yan R, Jiang MN,
Li L, Zhang LX, Zhao XG, Yuan GP, Xu B and Liu XM: Serum YKL-40 and
Serum Krebs von den lungen-6 as potential predictive biomarkers for
rheumatoid arthritis-associated interstitial lung disease. Immunol
Invest. 53:989–1000. 2024.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Liu N, Fan X, Shao Y, Chen S, Wang T, Yao
T and Chen X: Resveratrol attenuates inflammation and fibrosis in
rheumatoid arthritis-associated interstitial lung disease via the
AKT/TMEM175 pathway. J Transl Med. 22(457)2024.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Liu H, Yang Y, Zhang J and Li X:
Baricitinib improves pulmonary fibrosis in mice with rheumatoid
arthritis-associated interstitial lung disease by inhibiting the
Jak2/Stat3 signaling pathway. Adv Rheumatol. 63(45)2023.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Venetsanopoulou AI, Ntinopoulou M,
Papagianni E, Koletsos N, Voulgari PV and Chrysanthopoulou A:
Neutrophil extracellular traps as immunofibrotic mediators in
RA-ILD; pilot evaluation of the nintedanib therapy. Front Immunol.
15(1480594)2024.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Shoda T, Kotani T, Mitsuhiro K, Yoshikawa
A, Wada Y, Makino H, Osuga K and Takeuchi T: The therapeutic
efficacy of abatacept for rheumatoid arthritis-associated
interstitial lung disease: Insights from a 12-month trial using
semi-quantitative chest high-resolution computed tomography
imaging. J Clin Med. 13(5871)2024.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Wang S, Liu M, Li X, Zhang J, Wang F,
Zhang C, Roden A, Ryu JH, Warrington KJ, Sun J, et al: Canonical
and noncanonical regulatory roles for JAK2 in the pathogenesis of
rheumatoid arthritis-associated interstitial lung disease and
idiopathic pulmonary fibrosis. FASEB J. 36(e22336)2022.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Rodríguez Portal JA, Brito García N, Díaz
Del Campo Fontecha P, Valenzuela C, Ortiz AM, Nieto MA,
Mena-Vázquez N, Cano-Jiménez E, Castellví I, Aburto M, et al:
SER-SEPAR recommendations for the management of rheumatoid
arthritis-related interstitial lung disease. Part 1: Epidemiology,
risk factors and prognosis. Reumatol Clin (Engl Ed). 18:443–452.
2022.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Albrecht K, Strangfeld A, Marschall U and
Callhoff J: Interstitial lung disease in rheumatoid arthritis:
Incidence, prevalence and related drug prescriptions between 2007
and 2020. RMD Open. 9(e002777)2023.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Huang Z, Wu T, Lu R, Zhou H, Zhang Y,
Huang L, Gan Y and He H: Prevalence and clinical significance of
anti-neutrophil cytoplasmic antibodies in rheumatoid
arthritis-associated interstitial lung disease. BMC Pulm Med.
25(177)2025.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Aletaha D, Neogi T, Silman AJ, Funovits J,
Felson DT, Bingham CO III, Birnbaum NS, Burmester GR, Bykerk VP,
Cohen MD, et al: 2010 Rheumatoid arthritis classification criteria:
An American college of rheumatology/European league against
rheumatism collaborative initiative. Arthritis Rheum. 62:2569–2581.
2010.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Raghu G, Remy-Jardin M, Myers JL, Richeldi
L, Ryerson CJ, Lederer DJ, Behr J, Cottin V, Danoff SK, Morell F,
et al: Diagnosis of idiopathic pulmonary fibrosis. An Official
ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care
Med. 198:e44–e68. 2018.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Kono M: New insights into the metabolism
of Th17 cells. Immunol Med. 46:15–24. 2023.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Zhang Y, Zhu J, Xiao K, Liu H, Du K, Wu D
and Zou Q: Single-cell sequencing of PBMC characterizes the
transformation of T cell subsets in the inflammatory
microenvironment of RA-ILD. Research Square: https://doi.org/10.21203/rs.3.rs-3990097/v1.
|
|
26
|
Jeong E, Hong H, Lee YA and Kim KS:
Potential rheumatoid arthritis-associated interstitial lung disease
treatment and computational approach for future drug development.
Int J Mol Sci. 25(2682)2024.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Liu C and Ge Y: Immune-related genes
associated with interstitial lung disease in dermatomyositis. Int J
Gen Med. 17:5261–5271. 2024.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Yang Z, Han R, Yin H, Li J, Cao Y, Guo R,
Sheng Y, Song L and Zhang Y: Mechanism of Lycopodii herba for
RA-ILD using integrated metabolomics and network pharmacology. Anal
Biochem. 648(114679)2022.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Wang C, Kong L, Kim S, Lee S, Oh S, Jo S,
Jang I and Kim TD: The role of IL-7 and IL-7R in cancer
pathophysiology and immunotherapy. Int J Mol Sci.
23(10412)2022.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Knuever J, Willenborg S, Ding X, Akyüz MD,
Partridge L, Niessen CM, Brüning JC and Eming SA: Myeloid
cell-restricted insulin/IGF-1 receptor deficiency protects against
skin inflammation. J Immunol. 195:5296–5308. 2015.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Wu SM, Tsai JJ, Pan HC, Arbiser JL, Elia L
and Sheu ML: Aggravation of pulmonary fibrosis after knocking down
the aryl hydrocarbon receptor in the insulin-like growth factor 1
receptor pathway. Br J Pharmacol. 179:3430–3451. 2022.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Liu Z, Peng Z, Lin H, Zhou K, Liang L, Cao
J, Huang Z and Mei J: Identifying potential drug targets for
idiopathic pulmonary fibrosis: A mendelian randomization study
based on the druggable genes. Respir Res. 25(217)2024.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Bauer Y, White ES, de Bernard S,
Cornelisse P, Leconte I, Morganti A, Roux S and Nayler O: MMP-7 is
a predictive biomarker of disease progression in patients with
idiopathic pulmonary fibrosis. ERJ Open Res. 3:00074–2016.
2017.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Ramadas RA, Ewart SL, Medoff BD and LeVine
AM: Interleukin-1 family member 9 stimulates chemokine production
and neutrophil influx in mouse lungs. Am J Respir Cell Mol Biol.
44:134–145. 2010.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Huaux F, Gharaee-Kermani M, Liu T, Morel
V, McGarry B, Ullenbruch M, Kunkel SL, Wang J, Xing Z and Phan SH:
Role of Eotaxin-1 (CCL11) and CC chemokine receptor 3 (CCR3) in
bleomycin-induced lung injury and fibrosis. Am J Pathol.
167:1485–1496. 2005.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Yuan L, Zou C, Ge W, Liu Y, Hu B, Wang J,
Lin B, Li Y and Ma E: A novel cathepsin L inhibitor prevents the
progression of idiopathic pulmonary fibrosis. Bioorg Chem.
94(103417)2020.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Novelli F, Neri T, Tavanti L, Armani C,
Noce C, Falaschi F, Bartoli ML, Martino F, Palla A, Celi A and
Paggiaro P: Procoagulant, tissue factor-bearing microparticles in
bronchoalveolar lavage of interstitial lung disease patients: An
observational study. PLoS One. 9(e95013)2014.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Poole JA, Thiele GM, Janike K, Nelson AJ,
Duryee MJ, Rentfro K, England BR, Romberger DJ, Carrington JM, Wang
D, et al: Combined collagen-induced arthritis and organic
dust-induced airway inflammation to model inflammatory lung disease
in rheumatoid arthritis. J Bone Miner Res. 34:1733–1743.
2019.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Schuliga M, Kanwal A, Read J, Blokland
KEC, Burgess JK, Prêle CM, Mutsaers SE, Grainge C, Thomson C, James
A, et al: A cGAS-dependent response links DNA damage and senescence
in alveolar epithelial cells: A potential drug target in IPF. Am J
Physiol Lung Cell Mol Physiol. 321:L859–L871. 2021.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Cella G, Cipriani A, Tommasini A, Rampin
E, Sbarai A, Rocconi R, Mazzaro G and Luzzatto G: Tissue factor
pathway inhibitor (TFPI) antigen plasma level in patients with
interstitial lung disease before and after heparin administration.
Semin Thromb Hemost. 23:45–49. 1997.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Russo RC and Ryffel B: The chemokine
system as a key regulator of pulmonary fibrosis: Converging
pathways in human idiopathic pulmonary fibrosis (IPF) and the
bleomycin-induced lung fibrosis model in mice. Cells.
13(2058)2024.PubMed/NCBI View Article : Google Scholar
|
|
42
|
He CH, Lv JM, Khan GJ, Duan H, Wang W,
Zhai KF, Zou GA and Aisa HA: Total flavonoid extract from
Dracocephalum moldavica L. improves pulmonary fibrosis by reducing
inflammation and inhibiting the hedgehog signaling pathway.
Phytother Res. 37:2745–2758. 2023.PubMed/NCBI View
Article : Google Scholar
|
|
43
|
Feng F, Wang LJ, Li JC, Chen TT and Liu L:
Role of heparanase in ARDS through autophagy and exosome pathway
(review). Front Pharmacol. 14(1200782)2023.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Li Y, Zhao J, Yin Y, Li K, Zhang C and
Zheng Y: The role of IL-6 in fibrotic diseases: Molecular and
cellular mechanisms. Int J Biol Sci. 18:5405–5414. 2022.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Cai Z, Deng X, Jia J, Wang D and Yuan G:
Ectodysplasin A/Ectodysplasin A receptor system and their roles in
multiple diseases. Front Physiol. 12(788411)2021.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Zheng S, Yang B, Li L, Chen M, Zhang L,
Chi W, Shao ZM, Xiu B, Chi Y and Wu J: RTAM promotes antitumor
immune response in triple negative breast cancer by enhancing CD8+
T cell infiltration. Int Immunopharmacol.
129(111625)2024.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Liao Y, Ke B, Long X, Xu J and Wu Y:
Upregulated expression of IL2RB causes disorder of immune
microenvironment in patients with Kawasaki disease. Biomed Res Int.
2022(2114699)2022.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Pastor Bandeira I, de Almeida Franzoi AE,
Murillo Wollmann G, de Medeiros Junior WLG, Nogueira Brandão W,
Schatzmann Peron JP, Becker J, Nascimento OJM and Magno Gonçalves
MV: Interleukin-31 and soluble CD40L: New candidate serum
biomarkers that predict therapeutic response in multiple sclerosis.
Neurol Sci. 43:6271–6278. 2022.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Chen CC, Chen CY, Yeh CT, Liu YT, Leu YL,
Chuang WY, Shih YH, Chou LF, Shieh TM and Wang TH: Corylin
attenuates CCl4-induced liver fibrosis in mice by regulating the
GAS6/AXL signaling pathway in hepatic stellate cells. Int J Mol
Sci. 24(16936)2023.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Fiebeler A, Park JK, Muller DN, Lindschau
C, Mengel M, Merkel S, Banas B, Luft FC and Haller H: Growth arrest
specific protein 6/Axl signaling in human inflammatory renal
diseases. Am J Kidney Dis. 43:286–295. 2004.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Cao Z, Li J, Hu W, Xu J, Zhao F, Wang Y,
Qin S, Liu M, Wang P, Duan J, et al: Near-infrared imaging agent
ABSi-148 alleviates CA IX-mediated hypoxic fibrosis in
inflammation-cancer transition. Adv Healthc Mater.
18(e2404935)2025.PubMed/NCBI View Article : Google Scholar
|
